Results 161 to 170 of about 41,602 (290)

Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH‐Bladder Cancer: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
Timeline of treatment and sustained partial response in a patient with HER2 2+/FISH‐ bladder cancer (October 2019 – June 2024). ABSTRACT Disitamab Vedotin achieved durable partial response (> 8 months PFS) in advanced HER2 2+/FISH‐ bladder cancer after first‐line chemo‐immunotherapy progression.
Zhi‐ruo Jin   +8 more
wiley   +1 more source

Colocolic intussusception caused by a descending colon lipoma in an adult: a rare case report. [PDF]

open access: yesInt J Surg Case Rep
Acharya A   +4 more
europepmc   +1 more source

Lansoprazole‐Induced Microscopic Colitis Mimicking Anticancer Drug‐Related Diarrhea During Lenvatinib and Pembrolizumab Combination Therapy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Persistent diarrhea during anticancer therapy may not be attributable to anticancer agents. Our patient presented with diarrhea during lenvatinib–pembrolizumab therapy, likely caused by lansoprazole‐induced microscopic colitis. Even when symptoms closely resemble anticancer drug or immune‐related colitis, drug‐induced colitis due to ...
Shinichi Maruyama   +6 more
wiley   +1 more source

Primary leiomyosarcoma of the descending colon initially non-diagnostic on biopsy: a case report. [PDF]

open access: yesWorld J Surg Oncol
Pyo DH   +6 more
europepmc   +1 more source

Blood‐based cell‐free DNA and multitarget stool RNA screening tests to detect colorectal cancer: A systematic review

open access: yesCancer, Volume 132, Issue 11, 1 June 2026.
Abstract Two new tests, a cell‐free DNA (cfDNA) blood‐based test (BBT) and multitarget stool RNA (mt‐sRNA) test with in‐laboratory fecal immunochemical testing, were recently approved by the US Food and Drug Administration, and a second BBT is under review. These tests have the potential to overcome barriers to screening.
Karli K. Kondo   +4 more
wiley   +1 more source

Diabetes and Cancer‐Specific Survival: A Nationwide Population‐Based Cohort Study Across Multiple Cancer Sites

open access: yesCancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Cancer patients with concurrent diabetes generally show poorer survival compared with nondiabetic patients. Aims We examined the relationship between Type 2 diabetes and cancer‐specific survival in the 13 most common cancer sites within a large population‐based cohort in Finland.
Petrus Lohi   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy